Creative Bio-Peptides, Inc., an emerging drug development company focused on the development of leading-edge multi-chemokine antagonist therapeutic peptides for neuroinflammatory/neurodegenerative conditions, has been awarded $5.8M in non-dilutive funding from three NIH agencies.

The two grants each represent multi-million-dollar funding over a 2-year period as part of the NIH’s HEAL Initiative, committed to providing safe non-opioid pain treatments for the 50 million Americans living with daily chronic pain as well as the 2 million Americans living with dependency or addiction to opioids.

The National Institute on Drug Abuse (NIDA) SBIR phase II award is for the further development of Creative Bio-Peptides’ oral formulation of chemokine antagonist RAP-103, a safe, non-opioid treatment for OUD that can block motivation to maintain opioid use and mitigate signs of opioid withdrawal, as demonstrated in a previous phase I grant from NIDA.

The National Institute of Neurological Disorders and Stroke award is to develop RAP-103 as a non-opioid treatment for the relief of chronic pain. Pre-clinical data supports evidence that these oral peptides block and reverse neuropathic pain by blocking microglial activation and monocyte infiltration, reversing neuro-inflammation, and repairing nerve damage. Read More